Drug Trial Radar · NCT03749317
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Feb 20, 2023
Primary completion
Apr 30, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- IVIEW Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis
Conditions
- Adenoviral Conjunctivitis
Interventions
IVIEW-1201Drug
IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
PlaceboDrug
Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical resolution by assessment of bulbar conjunctival injection and watery conjunctival dischargeTime frame: Day 6 +/- 1 Day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Disha Eye Hospital
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.